Open Access
ARTICLE
Percutaneous Closure of Patent Foramen Ovale and Secundum Atrial Septal Defects with the GORE® CARDIOFORM Septal Occluder: Incidence and Implications of Device Wire Frame Fracture
Biagio Castaldi1,*, Giulio Cabrelle1, Massimo Padalino2, Vladimiro Vida2, Ornella Milanesi1, Giovanni Di Salvo1
1 Department of Women’s and Children’s Health, University of Padua, Padua, Italy
2 Department of Cardio-Thoracic Sciences, University of Padua, Padua, Italy
* Corresponding Author: Biagio Castaldi. Email:
Congenital Heart Disease 2020, 15(5), 347-360. https://doi.org/10.32604/CHD.2020.012750
Received 13 July 2020; Accepted 20 August 2020; Issue published 23 September 2020
Abstract
Background: Trans-catheter closure has become the treatment of
choice for patent foramen ovale (PFO) and ostium secundum atrial septal defects
(ASD). A wide variety of devices are commercially available, however, concerns
have been raised about the risk of cardiac erosion associated with stiff/rigid
devices. The GORE® CARDIOFORM Septal Occluder (GSO) is a double-disc,
soft and conformable device with no reported incidence of cardiac erosions. However, wire frame fracture (WFF) have been reported.
Aim: To assess the incidence
and clinical significance of WFF after GSO implantation in paediatric patients.
Methods: Seventy-seven consecutive patients were enrolled. Periprocedural and
follow-up assessments included clinical, echocardiographic, and X-ray fluoroscopy examinations.
Results: Mean patient age was 10.0 ± 3.9 years. In 7 patients
the indication was PFO closure, in 70 patients ASD closure. Mean follow-up period was 3.1 ± 1.3 years. X-ray fluoroscopy evaluations were available for
60 patients. WFF was detected in a total of 22 (35.4%) GSO devices. Three
WFF compromised the outer perimeter of the device. Incidence of WFF was higher for the 30 mm GSO device (58%;
p = 0.001). A multivariate analysis confirmed
that the GSO device diameter (
p = 0.013; F = 6.7) and stretched ASD diameter
(
p = 0.034; F = 4.38) were independent factors related to WFF. WFF did not result
in any clinical sequelae/patient harm. Residual shunt was observed in 4 patients
(5%) at 24 hours following procedure. Conclusion: The GSO device is safe and
effective for PFO and ASD closure. WFF was not associated with clinical sequelae
or device instability. Device diameter strongly correlates with incidence of WFF.
Keywords
Cite This Article
Castaldi, B., Cabrelle, G., Padalino, M., Vida, V., Milanesi, O. et al. (2020). Percutaneous Closure of Patent Foramen Ovale and Secundum Atrial Septal Defects with the GORE® CARDIOFORM Septal Occluder: Incidence and Implications of Device Wire Frame Fracture.
Congenital Heart Disease, 15(5), 347–360. https://doi.org/10.32604/CHD.2020.012750
Citations